Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).
Last trade$8.61
Day change+$0.32 (+3.86%)
Day range$8.07 – $8.70
Volume539,694
Market cap$248M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$248.07M
Price / earnings
7.69×
Price / book
0.86×
Price / sales
4.62×
EV / sales
-0.77×
EV / EBITDA
-2.22×
Profitability
Earnings per share
$1.08
Return on assets
10.85%
Return on equity
11.21%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
56.34×
Quick ratio
56.34×
Cash ratio
56.05×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$20.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for QTTB, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$53.74M
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$53.74M
$0
$0
$0
$0
Selling, general and administrative
$5.51M
$4.86M
$4.5M
$4.54M
$4.02M
$4.01M
$5.1M
$3.98M
Research and development
$5.15M
$4.26M
$3.22M
$3.32M
$3.56M
$5.16M
$7.12M
$10.55M
Total operating expenses
$10.66M
$9.12M
$7.72M
$7.86M
$7.58M
$9.17M
$12.23M
$14.53M
Operating income
-$10.66M
-$9.12M
-$7.72M
$45.88M
-$7.58M
-$9.17M
-$12.23M
-$14.53M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$8.92M
-$8.95M
-$7.61M
$57.73M
-$7.39M
-$9.49M
-$11.03M
-$14.17M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$21K
Net income
-$8.92M
-$8.95M
-$7.61M
$57.73M
-$7.39M
-$9.49M
-$11.03M
-$14.19M
Net income attributable to common shareholders
-$8.92M
-$8.95M
-$7.61M
$57.73M
-$7.39M
-$9.49M
-$11.03M
-$14.19M
EBITDA
-$10.58M
-$9.03M
-$7.63M
$45.97M
-$7.49M
-$9.08M
-$12.11M
-$14.41M
Basic earnings per share
-$0.26
-$0.44
-$0.54
$4.59
-$0.60
-$0.78
-$0.90
-$1.16
Diluted earnings per share
-$0.26
-$0.44
-$0.54
$4.57
-$0.60
-$0.78
-$0.90
-$1.16
Recent news
Company coverage with links to the original publishers.
Q32 Bio (NASDAQ: QTTB) announced a $55 million private placement, issuing 6.725 million shares at $8 per share to fund development of therapies for alopecia areata and immune-mediated diseases. The stock gained 9.84% on Friday, trading at $11.32, supported by strong technical momentum with a golden cross formation and analyst consensus rating of Strong Buy with a $13.50 price target.
Q32 Bio sold its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics for $12 million in upfront payments, with potential milestone payments up to $592 million, causing its stock to surge by over 115%.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.
Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday.
Here are some other stocks moving in today's mid-day session.
Gainers
Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.
Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives.
SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday.
Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday.
Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies.
Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo.
Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650.
HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday.
Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18.
Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.